Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference
Anavex Life Sciences (NASDAQ:AVXL) is prioritizing upcoming pivotal studies and continued regulatory engagement as it seeks potential pathways to market authorization for its oral central nervous system (CNS) drug candidate blarcamesine, company executives said during a Needham conference session hosted by biotech analyst Ami Fadia. Focus on oral “personalized brain medicine” President and CEO Christopher […]
17 Apr 09:10 · The Markets Daily